Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Feb 1;57(5):612-8.
doi: 10.1016/j.jacc.2010.08.643.

Genetic warfarin dosing: tables versus algorithms

Affiliations
Comparative Study

Genetic warfarin dosing: tables versus algorithms

Brian S Finkelman et al. J Am Coll Cardiol. .

Abstract

Objectives: The aim of this study was to compare the accuracy of genetic tables and formal pharmacogenetic algorithms for warfarin dosing.

Background: Pharmacogenetic algorithms based on regression equations can predict warfarin dose, but they require detailed mathematical calculations. A simpler alternative, recently added to the warfarin label by the U.S. Food and Drug Administration, is to use genotype-stratified tables to estimate warfarin dose. This table may potentially increase the use of pharmacogenetic warfarin dosing in clinical practice; however, its accuracy has not been quantified.

Methods: A retrospective cohort study of 1,378 patients from 3 anticoagulation centers was conducted. Inclusion criteria were stable therapeutic warfarin dose and complete genetic and clinical data. Five dose prediction methods were compared: 2 methods using only clinical information (empiric 5 mg/day dosing and a formal clinical algorithm), 2 genetic tables (the new warfarin label table and a table based on mean dose stratified by genotype), and 1 formal pharmacogenetic algorithm, using both clinical and genetic information. For each method, the proportion of patients whose predicted doses were within 20% of their actual therapeutic doses was determined. Dosing methods were compared using McNemar's chi-square test.

Results: Warfarin dose prediction was significantly more accurate (all p < 0.001) with the pharmacogenetic algorithm (52%) than with all other methods: empiric dosing (37%; odds ratio [OR]: 2.2), clinical algorithm (39%; OR: 2.2), warfarin label (43%; OR: 1.8), and genotype mean dose table (44%; OR: 1.9).

Conclusions: Although genetic tables predicted warfarin dose better than empiric dosing, formal pharmacogenetic algorithms were the most accurate.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Dosing Method Accuracy
The proportion dosed within 20% of the stable therapeutic dose was calculated for each dosing method. Having a predicted dose within 20% of the therapeutic dose was considered a clinically meaningful degree of accuracy. Error bars indicate ±1 SE.
Figure 2
Figure 2. Two-Way Comparisons of Dosing Methods
The proportion dosed within 20% of stable therapeutic dose was compared using McNemar’s chi-square test. The resultant odds ratio reflects the odds of a patient’s being properly dosed by the first method versus the second. Error bars represent exact 95% confidence intervals.
Figure 3
Figure 3. Dosing Method Accuracy
The proportions dosed below 80%, within 20%, and above 120% of the stable therapeutic dose were calculated for each dosing method.

References

    1. Gage B, Lesko L. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25:45–51. - PubMed
    1. Brisotol-Meyers Squibb Company. [Accessed February 2, 2010.];Coumadin® tablets (warfarin sodium tablets, USP) crystalline; Coumadin® for injection (warfarin sodium for injection, USP) Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf.
    1. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326–31. - PMC - PubMed
    1. Klein T, Altman R, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–64. - PMC - PubMed
    1. Voora D, Eby C, Linder M, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005;93:700–5. - PubMed

Publication types